随着宠物成为不可或缺的"家庭成员"，携宠出行、人宠共游已成为城市生活的新风尚与新消费热点。 然而，"带毛孩子去哪儿？"却成了众多宠主面临的现实难题。信息不对称、政策不明晰、体验不确定， 常让一次计划中的欢乐出行变成尴尬与无奈的遭遇。 而另一位边牧犬主人的心声，则代表了更深层次的诉求："我们希望能有更多超市、公园等公共空间向 狗狗开放，让它们也能享受城市生活。同时，也特别希望所有宠物主人都能自觉牵好绳、做好清理，这 是友好共存的基础。" 正是洞察到这些痛点与需求，"粤宠同行"项目应运而生。 启动仪式上，广东省宠物行业协会荣誉会长麦春华指出，中国宠物消费市场规模预计2025年将突破5000 亿，专业人才缺口高达百万，行业正站在黄金时代的起点。 为系统化推动宠物友好生态建设，助力万亿"它经济"规范化、高质量发展，12月28日，由南方都市报联 合广东省景区行业协会、广东省宠物行业协会发起，勃林格殷格翰特别支持的 "粤宠同行"宠物友好空 间测评项目，在广州汉溪K11购物艺术中心正式启动，并同期举办了"粤宠同行嘉年华"沉浸式的人宠互 动盛会。 宠物出行之困 从"被拒之门外"到"期待友好公约" 活动现场，南都N视频记者随机 ...

【#官方通报医院私换狂犬疫苗事件#：护士扫码录入错误 涉事人员被问责】#贵州通报花310元打80元 狂犬疫苗# 12月20日晚，贵州桐梓县卫健局针对居民反映"医院私自更换狂犬疫苗"事件发布通报。17 日，居民赵某某在海校街道社区卫生服务中心接种狂犬疫苗时，护士工作失误，将其实际接种的310元/ 剂次成都康华生物疫苗，误录入为前一接种者使用的80元/剂次山东亦度生物疫苗包装盒信息，导致系 统显示与实际接种疫苗不符。经核查库存与接种记录，该中心未更换药品。桐梓县卫健局对涉事机构负 责人通报批评，对当班护士予以批评教育。（新京报） 转自：今晚报 （来源：今晚报） ...

百克生物本次上市发行费用为1.05亿元，其中，保荐机构、主承销商中信证券股份有限公司和联席 主承销商国泰君安证券股份有限公司获得承销保荐费9004.06万元。 本次发行最终战略配售数量为825.61万股，约占发行总数量的20.00%，与初始战略配售数量的差 额744股回拨至网下发行。依据《上海证券交易所科创板股票发行与承销业务指引》第十八条规定，本 次发行保荐机构相关子公司中信证券投资有限公司最终获配股份数量为165.06万股，获配金额6000.00 万元。 (责任编辑：徐自立) 中国经济网北京12月15日讯 百克生物（688276.SH）今日收报19.37元，跌幅2.42%。 百克生物于2021年6月25日在上交所科创板上市，公司公开发行股票数量为4128.41万股，占本次 发行后总股本的10.00%，发行价格为36.35元/股，保荐机构为中信证券股份有限公司，保荐代表人为 董芷汝、朱绍辉。目前该股股价处于破发状态。 百克生物本次募集资金总额为15.01亿元，扣除发行费用后，实际募集资金净额为13.96亿元。百 克生物最终募集资金净额比原计划少2.85亿元。百克生物于2021年6月21日披露的招股说明书显示 ...

格隆汇12月15日丨生物股份(600201.SH)在投资者互动平台表示，公司狂犬疫苗和猫三联疫苗均在售。 猫三联疫苗通过线上平台与线下联动，前三季度销量取得较大幅增长。 ...

格隆汇12月15日丨生物股份(600201.SH)在投资者互动平台表示，公司狂犬疫苗和猫三联疫苗均在售。 猫三联疫苗通过线上平台与线下联动，前三季度销量取得较大幅增长。 ...

辽宁成大是其中的代表。公开信息显示，辽宁成大前身为辽宁省纺织品进出口公司，1996年完成主板上 市，曾布局生物医药、金融投资、供应链贸易、能源开发等多个领域，随着行业环境变化，企业战略重 心开始向科技领域调整。 12月5日，由南方财经全媒体集团主办、21世纪数字传媒承办的南方财经论坛"21世纪卓越董事会年 会"在广州南方财经大厦召开。大会以"新蓝图，新机遇"为主题，辽宁成大董事长徐飚现场出席会议， 并以辽宁成大的发展实践出发，阐述了技术创新与新质生产力对企业发展的重要意义。 徐飚表示："站在今天看资本市场，看产业发展趋势，我们认为要聚焦科技，要用科技来重塑公司的价 值。" 当前，全球科技革命与产业变革加速演进，技术创新成为影响产业格局的关键因素，AI、生物制造等 新技术与实体经济的融合持续加深，新质生产力逐步成为经济高质量发展的重要驱动。在此背景下，传 统企业向科技型、创新型转型成为行业常见趋势，各领域企业多通过调整战略、聚焦创新赛道以应对市 场变化。 为集中资源发展核心赛道，辽宁成大采取"做减法、聚核心"的战略调整。徐飚介绍："我们首先适当地 做一些减法，逐步退出非核心业务，将资源向科技新兴产业倾斜。" 2 ...

Core Points - The article discusses a ten-year vaccine collaboration between Sinovac and the Brazilian Ministry of Health, focusing on the establishment of a vaccine production platform in Brazil [1] - Sinovac will provide approximately 60 million doses of varicella and rabies vaccines to Brazil over the next decade, valued at over $700 million [1] - The signing ceremony took place in São Paulo, attended by key Brazilian officials and Sinovac's Vice President Meng Weining, who emphasized the importance of investing in vaccines for public health [1] Group 1 - Sinovac signed two PDP (Product Development Partnership) projects with Brazil's Ministry of Health [1] - The collaboration aims to enhance Brazil's local vaccine production capacity [1] - The partnership will benefit not only Brazil but also other countries in the Global South [1] Group 2 - The total value of the vaccine supply agreement is over $700 million [1] - The agreement includes the provision of around 60 million doses of vaccines over ten years [1] - The initiative is part of Sinovac's mission to strengthen public health systems and meet national needs in Brazil [1]

Core Viewpoint - Chengdu Kanghua Biological Products Co., Ltd. has officially completed the acquisition of controlling interest by Shanghai Biopharmaceutical M&A Fund, marking a new strategic development phase for the company [1][2] Group 1: Acquisition and Strategic Development - The acquisition by Shanghai Biopharmaceutical M&A Fund through Wankexin Biotechnology Partnership is expected to propel Kanghua Biological into a new stage of high-quality development [1] - The new leadership at Kanghua Biological emphasizes the need for fresh resources to drive growth, indicating a collaborative effort with the acquiring fund [2] Group 2: Industry Context and Opportunities - The Chinese vaccine industry is presented with development opportunities, supported by an improving policy environment, which could benefit Kanghua Biological in resource integration and establishing a comprehensive rabies prevention service system [2] - The collaboration aims to enhance synergy between Shanghai and Chengdu in research, clinical trials, and industrialization, leveraging capital and industry [2] Group 3: Partnerships and Strategic Agreements - Kanghua Biological has signed strategic agreements with several partners, including Shanghai Pharmaceuticals and eight service providers, to support market positioning and channel expansion [2]

Core Insights - The completion of the acquisition of Kanghua Biological by Shanghai Biopharmaceutical M&A Fund through Wankexin Biological was marked by a ceremony in Chengdu on November 27, 2025 [1] Group 1: Company Developments - New Kanghua Biological aims to introduce fresh capital to drive development, indicating a strategic shift following the acquisition [3] - The new chairman of Kanghua Biological, Liu Dawei, emphasized the company's established reputation and the importance of capital and industry integration for future growth [4] - Strategic agreements were signed with several partners and professional institutions to support market layout and channel expansion for New Kanghua Biological [4] Group 2: Industry Context - The president of the China Vaccine Industry Association highlighted the opportunities in China's vaccine industry, noting an improving policy environment that could benefit New Kanghua Biological [3] - The collaboration between Shanghai and Chengdu in the biopharmaceutical sector is expected to enhance research and development, clinical practices, and industrial cooperation [4]

Core Viewpoint - The acquisition of Kanghua Biotech by the Shanghai Biopharmaceutical M&A Fund through Wankexin Biotech marks a significant development in the biopharmaceutical industry, aiming to enhance Kanghua's capabilities and market position in the vaccine sector [1]. Group 1: Acquisition Details - The acquisition was officially completed on November 27, 2025, during the unveiling and ecological cooperation conference held in Chengdu [1]. - The event was attended by various leaders and representatives from the biopharmaceutical industry, indicating strong support and interest in the collaboration [3]. Group 2: Strategic Vision and Goals - Kanghua Biotech's Vice Chairman emphasized the need for fresh blood to drive development, highlighting the importance of the partnership with the M&A fund for future progress [3]. - The President of Shanghai Shiyuan Group expressed hopes that the acquisition would facilitate collaboration between Shanghai and Chengdu in research, clinical trials, and industrialization [7]. Group 3: Industry Context and Opportunities - The President of the China Vaccine Industry Association noted that the vaccine industry in China is facing development opportunities, with an improving policy environment that could benefit Kanghua Biotech [5]. - Kanghua Biotech aims to leverage its existing rabies vaccine foundation to build a comprehensive rabies prevention service system [5]. Group 4: Strategic Partnerships - During the conference, Kanghua Biotech signed strategic agreements with several partners, including Shanghai Pharmaceutical Holdings and eight service providers, to support market expansion and channel development [12][14].